Literature DB >> 3896351

Serum immunoglobulin levels following allogeneic bone marrow transplantation.

C Perreault, M Giasson, M Gyger, R Belanger, M David, Y Bonny, J Boileau, R Barcelo, J P Moquin.   

Abstract

In order to study the posttransplant evolution of serum immunoglobulin levels, we measured serum IgG, IgA and IgM levels in 50 recipients of allogeneic bone marrow before transplantation and at different intervals thereafter (days 39, 120, 365 and 730). IgG and IgM levels were depressed for 1 year and IgA levels for 2 years posttransplant. Immunoglobulin deficiency was more severe and prolonged in patients with graft versus-host-disease. Hypogammaglobulinemia may contribute to the frequent infections observed in these patients, especially those with chronic graft-versus-host disease.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3896351     DOI： 10.1007/bf00320027

Source DB:  PubMed          Journal:  Blut        ISSN： 0006-5242


  19 in total

Review 1.  Bone-marrow transplantation (second of two parts).

Authors:  E D Thomas; R Storb; R A Clift; A Fefer; L Johnson; P E Neiman; K G Lerner; H Glucksberg; C D Buckner
Journal:  N Engl J Med       Date:  1975-04-24       Impact factor: 91.245

2.  Analysis of late infections in 89 long-term survivors of bone marrow transplantation.

Authors:  K Atkinson; R Storb; R L Prentice; P L Weiden; R P Witherspoon; K Sullivan; D Noel; E D Thomas
Journal:  Blood       Date:  1979-04       Impact factor: 22.113

3.  Selective IgA deficiency: presentation of 30 cases and a review of the literature.

Authors:  A J Ammann; R Hong
Journal:  Medicine (Baltimore)       Date:  1971-05       Impact factor: 1.889

Review 4.  Immunologic reconstitution after human marrow grafting.

Authors:  R P Witherspoon; L G Lum; R Storb
Journal:  Semin Hematol       Date:  1984-01       Impact factor: 3.851

Review 5.  Infectious complications of bone marrow transplantation.

Authors:  D J Winston; W G Ho; R E Champlin; R P Gale
Journal:  Exp Hematol       Date:  1984-03       Impact factor: 3.084

6.  Immunological recovery in 48 patients following syngeneic marrow transplantation or hematological malignancy.

Authors:  R P Witherspoon; K Kopecky; R F Storb; N Flournoy; K M Sullivan; R Sosa; H J Deeg; H D Ochs; M A Cheever; A Fefer; E D Thomas
Journal:  Transplantation       Date:  1982-02       Impact factor: 4.939

7.  Allogeneic marrow grafting for treatment of aplastic anemia.

Authors:  R Storb; E D Thomas; C D Buckner; R A Clift; F L Johnson; A Fefer; H Glucksberg; E R Giblett; K G Lerner; P Neiman
Journal:  Blood       Date:  1974-02       Impact factor: 22.113

Review 8.  Acute graft-versus-host disease after allogeneic bone marrow transplantation.

Authors:  C Perreault; M Gyger; J Boileau; Y Bonny; S Cousineau; M Lacombe; R Lavallee; E Tawil; G D'Angelo
Journal:  Can Med Assoc J       Date:  1983-11-01       Impact factor: 8.262

9.  Disordered salivary immunoglobulin secretion and sodium transport in human chronic graft-versus-host disease.

Authors:  K T Izutsu; K M Sullivan; M M Schubert; E L Truelove; H M Shulman; G E Sale; T H Morton; J C Rice; R P Witherspoon; R Storb; E D Thomas
Journal:  Transplantation       Date:  1983-05       Impact factor: 4.939

10.  In vitro regulation of immunoglobulin synthesis after marrow transplantation. I. T-cell and B-cell deficiencies in patients with and without chronic graft-versus-host disease.

Authors:  L G Lum; M C Seigneuret; R F Storb; R P Witherspoon; E D Thomas
Journal:  Blood       Date:  1981-09       Impact factor: 22.113
View more
  2 in total

Review 1.  Immune reconstitution post allogeneic transplant and the impact of immune recovery on the risk of infection.

Authors:  Rohtesh S Mehta; Katayoun Rezvani
Journal:  Virulence       Date:  2016-07-06       Impact factor: 5.882

2.  IgG subclass levels and immune reconstitution after T cell-depleted allogeneic bone marrow transplantation.

Authors:  S M Kelsey; M W Lowdell; A C Newland
Journal:  Clin Exp Immunol       Date:  1990-06       Impact factor: 4.330
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.